Recordati Industria Chimica e Farmaceutica S.p.A. (REC.MI)

50,75 +0,55 (+1,10 %) À la clôture : 05:35PM CEST

Recordati Industria Chimica e Farmaceutica S.p.A.

Via Matteo Civitali,1
Milan, MI 20148
Italy
39 02 487871
https://www.recordati.com

Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers - General
Employés à temps plein: 4 455

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Dr. Robert Koremans M.D.	CEO & Director	1,81M	S.O.	1962
Mr. Luigi Felice La Corte	Group CFO & Executive Director	948k	S.O.	1969
Ms. Cathrin Petty	Executive Director	S.O.	S.O.	1973
Mr. Giampiero Mazza	Executive Director	S.O.	S.O.	1969
Mr. Giorgio De Palma	Executive Director	S.O.	S.O.	1974
Ms. Eugenia Litz	VP & Head of Investor Relations	S.O.	S.O.	S.O.
Ms. Bibianne Bon	Group Chief Legal Officer	S.O.	S.O.	S.O.
Ms. Laura Conti	Group Communications Director	S.O.	S.O.	S.O.
Mr. Gabriele Finzi	Executive VP of Corporate Development, Licensing & Innovation	S.O.	S.O.	S.O.
Ms. Alessandra Abate	Group Chief People & Culture Officer	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2022 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en EUR.

Description

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Recordati Industria Chimica e Farmaceutica S.p.A. en date du 1 mai 2024 est 5. Les scores principaux sont Audit : 8; Société : 3; Droits des actionnaires : 3; Compensation : 7.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.